Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 in Advanced Cutaneous Squamous Cell Carcinoma
2022-502476-23-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of incb099280 in cutaneous squamous cell carcinoma (cSCC), sponsored by Incyte. Primary endpoints: Objective response rate, Incidence of treatment-emergent adverse events and 1 more. Started Oct 2023; status: completed.
02
Drugs
incb099280
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2022-502476-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502476-23-00.